DexCom, IncNasdaq: DXCM
Health Care · Health Care Equipment
$74.77
+3.99%
Vol: 411K
Research Digest
Monday, June 15, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21DexCom surged 6%+ after Investor Day setting 10% organic growth target through 2030 and $1B buybackPositive▶
DexCom held its Investor Day on May 14, 2026, announcing aggressive 2030 targets including 10%+ annual organic revenue growth, non-GAAP gross margin of 67-69% (vs prior 63-64%), and non-GAAP operating margin of 29-30% (vs prior 23-23.5%). The company also announced a new $1B share repurchase program through mid-2027 and plans to return at least 50% of annual free cash flow to buybacks. DexCom revealed governance enhancements following collaboration with activist Elliott Investment Management, adding two more independent directors. Product roadmap centers on G7 15 Day (rolling out 2026) and next-gen G8 (designed 50% smaller, more accurate, lower cost) targeted for late 2027/early 2028. Canaccord lifted target to $100. Risk: execution risk on long-term targets and competitive intensity in CGM market.
May 20Dexcom unveiled 2030 targets of 10%+ organic growth and $1B buyback at May 14 Investor Day, sending shares 6% higherPositive▶
At its May 14, 2026 Investor Day, Dexcom set ambitious 2030 targets: more than 10% organic revenue growth annually through 2030, gross margin of 67-69%, operating margin of 29-30%, and EBITDA margin of 36-37%. The company announced a fresh $1B share repurchase program through mid-2027, replacing a smaller prior plan. Q1 2026 delivered 12% organic sales growth to $1.19B with 22% adjusted operating margins. Activist Elliott Management is driving new independent directors and an Operations & Innovation Committee. Pipeline focus is G7 15-Day rolling out now and next-gen G8 in late 2027/early 2028 (50% smaller, lower cost). Shares jumped over 6% on the news.
May 19DexCom shares jumped 5.65% on May 18, 2026 as investors continued to digest the company's $1B buyback and 2030 double-digit growth targets unveiled at last week's Investor Day.Positive▶
DexCom stock climbed 5.65% on May 18, 2026 to extend the post-Investor Day rally, closing around $65.11. Management's May 14 presentation laid out long-term targets of more than 10% organic revenue growth annually through 2030, with non-GAAP gross margin of 67-69%, operating margin of 29-30%, and EBITDA margin of 36-37%. A fresh $1 billion share repurchase program through mid-2027 replaces the smaller prior plan, and management committed to returning at least 50% of annual free cash flow to buybacks. The company also detailed G7 15 Day adoption and a G8 sensor launch targeted for late 2027/early 2028 that will be 50% smaller and lower cost. Governance enhancements with Elliott Investment Management added two independent MedTech-experienced directors. The risk is execution on margin expansion against ongoing competition from Abbott's Libre franchise.
May 18DexCom Investor Day (May 14) unveils 10%+ annual organic growth target through 2030 and $1B share buyback; shares jumped 6%Positive▶
DexCom hosted Investor Day on May 14, 2026, setting long-term targets of >10% organic revenue growth annually through 2030, gross margin of 67-69%, operating margin of 29-30%, and EBITDA margin of 36-37%. The Board authorized a new $1.0 billion share repurchase program through June 30, 2027, replacing a prior plan with $250M remaining. Governance was enhanced by adding two independent directors with MedTech/operations experience and reconstituting an Operations and Innovation Committee, following engagement with Elliott Investment Management. Q1 delivered 12% organic growth to $1.19B with 22% adjusted operating margins. Shares rose 6.02% on May 15. Canaccord raised PT to $100; Benchmark initiated Buy with $77 target.
May 15DexCom hosted May 14 Investor Day and announced governance changes including Elliott Investment Management board settlement adding two independent directors.Positive▶
On May 14, 2026, DexCom held its Investor Day from 1:15-3:30 PM PDT outlining strategic vision and long-term financial outlook. Ahead of the event, DexCom announced governance changes - activist Elliott Investment Management took a stake and reached a settlement to add two independent directors to the board, with the new directors then collaborating to appoint two more directors with medical technology and operations expertise. Q1 2026 results released May 1 showed revenue of $1.19B (+15% YoY) and non-GAAP EPS $0.56 (19% above consensus). The company reaffirmed 2026 revenue guidance of $5.16B-$5.25B with raised margin outlook. DexCom is ceasing G6 CGM production next year to shift fully to G7. Multiple analysts (Jefferies, Goldman, Piper Sandler, Stifel, Truist, RBC, William Blair, BTIG) maintained Buy ratings. Stock at $61.14. Risks include U.S. growth moderation and reimbursement dynamics.
May 14DexCom hosting Investor Day May 14 to outline long-term financial outlook after strong Q1 with 15% revenue growth and 89% net income surgeMixed▶
DexCom hosting Investor Day Thursday May 14 from 1:15pm PT to outline long-term financial outlook and innovation roadmap. Q1 2026 revenue of $1.19B (+15%), EPS $0.52 vs $0.27 prior year, net income up 89% to $199.5M. Reaffirmed FY26 revenue guidance of $5.16-5.25B with raised margin outlook. Multiple analysts (Goldman, Piper, Raymond James, Stifel, Truist, RBC, William Blair, BTIG, Canaccord, Barclays) issued mixed PT changes post-print. Stock $58.63 May 13, slipping into Investor Day. Risk: G6 to G7 transition and competitive CGM landscape (Abbott Libre).
May 13Dexcom hosts Investor Day tomorrow (May 14) to outline long-term strategy after Q1 2026 revenue of $1.19B (+15% YoY) and reaffirmed FY guidance.Positive▶
DexCom hosts its Investor Day on Thursday, May 14, 2026 to outline long-term financial outlook and innovation priorities. Q1 2026 results showed revenue of $1.19B (+15% YoY) and net income of $199.5M with margin improvement. The company reaffirmed FY2026 revenue guidance of $5.16B-$5.25B. Analyst views remain mixed: Citi raised PT to $84 from $77 (Buy) while Barclays cut PT to $67 from $72 (Underweight). The consensus is Moderate Buy with average PT of $83.50. CGM coverage expansion has been a recent positive catalyst.
May 12DexCom hosts May 14 Investor Day to outline long-term outlook after Q1 2026 revenue of $1.19B (+15% YoY); Barclays cut PT to $67 from $72.Mixed▶
DexCom delivered Q1 2026 revenue of $1.19B, up 15% YoY, and reaffirmed full-year guidance of $5.16B-$5.25B, supported by international sales and margin improvements. The company is scheduled to host an Investor Day on May 14, 2026, to outline long-term financial outlook and innovation priorities. Analyst sentiment was mixed post-earnings, with Barclays lowering its price target to $67 from $72 while maintaining an Underweight rating. Shares traded in a narrow $61.00-$61.35 range on May 8. Investors look to the Investor Day for catalyst clarity.
May 11DexCom announced May 14 Investor Day after Q1 revenue of $1.19B grew 15% YoY; Barclays cut PT to $67Positive▶
DexCom reported Q1 2026 revenue of $1.19 billion (up 15% YoY) and net income of $199.5 million, reaffirming the 2026 revenue outlook of $5.16B-$5.25B while raising profitability guidance. The company announced an Investor Day on Thursday, May 14, 2026 from 1:15 PM PDT, where management will outline long-term financial outlook and innovation priorities. Barclays lowered the price target to $67 from $72 and maintained Underweight. However, overall analyst sentiment is positive with 2 Strong Buy, 18 Buy, 3 Hold, and 1 Sell ratings. Principal Financial Group disclosed $38.26 million in DXCM holdings. This matters because the May 14 Investor Day is a near-term catalyst that could drive multiple expansion if long-term targets impress.
May 8Dexcom Q1 2026 revenue up 15% YoY with strong margin expansion; Citi cuts price target to $79.Positive▶
Dexcom reported Q1 2026 revenue of $1.192B (up 15% YoY, 12% organic) with U.S. revenue up 11% and international up 26%. GAAP operating income reached $255.3M (21.4% margin, up 850 bps YoY) and non-GAAP operating income $264.4M (22.2% margin, up 840 bps YoY). The company expanded Dexcom G7 15-Day CGM across all U.S. channels and introduced enhanced Smart Meal Logging for Stelo platform. Full-year 2026 revenue guidance reaffirmed at $5.16B-$5.25B. Citi analyst Joanne Wuensch lowered price target to $79 from $84 while maintaining Buy rating.
May 7Dexcom Q1 2026 revenue $1.192B (+15% YoY) with strong international growth (26% YoY); Citi lowers price target to $79 from $84.Positive▶
Dexcom reported Q1 2026 revenue of $1.192 billion, up 15% YoY with 11% US growth and 26% international growth. GAAP operating income reached $255.3 million (21.4% margin), up 850 basis points YoY. The company expanded Dexcom G7 15-day CGM launch and introduced enhanced Stelo platform features. Clinical data presented at ATTD 2026 showed G7 significantly improved A1C for type 2 diabetes patients not using insulin. Citi analyst Joanne Wuensch lowered the price target to $79 from $84 while maintaining a Buy rating.
May 6Dexcom reports 15% revenue growth in Q1 2026 and reaffirms full-year guidancePositive▶
Dexcom reported Q1 2026 revenue of $1.192 billion (up 15% YoY) with GAAP operating income of $255.3 million (21.4% margin, up 850 bps YoY). U.S. revenue grew 11% and international revenue grew 26% on reported basis. The company expanded Dexcom G7 15 Day CGM launch across all U.S. channels and enhanced Stelo platform with Smart Meal Logging features. Full-year 2026 revenue guidance of $5.16B-$5.25B reaffirmed. Investor Day scheduled for May 14, 2026. Citi analyst lowered price target to $79 from $84 but maintains Buy rating. The company faces growth challenges but shows strong market demand for CGM systems.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| DXCMDEXCOM | $74.77 | +3.99% | +10.5% | 23.6x | 1.40 | $27.7B |
| ISRGINTUITIVE | $416.51 | -5.30% | -0.0% | 37.3x | 1.51 | $155.8B |
| ABTABBOTT | $88.21 | +0.50% | -0.2% | 14.5x | 0.65 | $152.9B |
| SYKSTRYKER | $310.30 | -1.02% | +0.1% | 18.8x | 0.81 | $120.2B |
| MDTMEDTRONIC | $80.25 | +2.69% | +1.1% | 12.9x | 0.63 | $100.3B |
| BSXBOSTON | $47.37 | -17.11% | +2.2% | 15.2x | 0.62 | $84.9B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.